New York advances regenerative medicine treatments

File A11301 ("New York advances regenerative medicine treatments") is before the New York Legislature and has not been decided. Latest step (May 11, 2026): In Assembly Committee.

New York file A11301, before the New York Legislature. Still to be decided as of 2026-05-11.

What it does

Patients gain clearer rules for experimental cell therapies New York patients will have access to regenerative medicine protocols under defined physician-use standards with mandatory disclosure requirements, though the specific treatments and timeline for availability depend on registry development and regulatory approval processes.

The bigger picture

New York positions itself as regenerative medicine hub The innovation program and registry framework could attract regenerative medicine research and biotech companies to New York, potentially creating jobs in life sciences while positioning the state as a leader in emerging cell-based treatments.

Official summary

Establishes the "New York regenerative medicine advancement and patient protection act" to build framework for regenerative medicine and cell-based therapies; creates patient protections and disclosure requirements; authorizes limited physician use of qualifying regenerative medicine protocols; creates a regenerative medicine registry; establishes the New York regenerative medicine innovation program.

Read the official record for A11301

See everything up for a vote · This week in New York · See what we have filed with the clerk